This excerpt taken from the AUXL 8-K filed Jan 21, 2010.
AUXILIUM SAFE HARBOR STATEMENT
This release contains forward-looking-statements within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the value of XIAFLEX, if approved, to Pfizers Specialty Care Business Units portfolio; working with Pfizer to secure the approval of XIAFLEX in the EU; Auxiliums receipt of a $15 million milestone payment from Pfizer; the number of patients with Dupuytrens contracture; products in development for Peyronies disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as believe, appears, may, could, will, estimate, continue, anticipate, intend, should, plan, expect, and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxiliums Annual Report on Form 10-K for the year ended December 31, 2008, in Auxiliums Quarterly Report on Form 10-Q for the period ended June 30, 2009 and in Auxiliums Quarterly Report on Form 10-Q for the period ended September 30, 2009 under the heading Risk Factors, which are on file with the Securities and Exchange Commission (the SEC) and may be accessed electronically by means of the SECs home page on the Internet at http://www.sec.gov or by means of Auxiliums home page on the Internet at http://www.Auxilium.com under the heading For Investors SEC Filings. There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and
uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.
In addition, forward-looking statements provide Auxiliums expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxiliums assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxiliums assessments as of any date subsequent to the date of this release.
Auxilium disclaims responsibility for statements above in About Pfizer Inc: Working together for a healthier world, which were provided by Pfizer for inclusion in this press release.